The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, KYTHERA Biopharmaceuticals's share price is €66.74.
KYTHERA Biopharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2015 was €0.01. Hence, KYTHERA Biopharmaceuticals's PS Ratio for today is 6,674.00.
Warning Sign:
KYTHERA Biopharmaceuticals Inc stock P/S Ratio (=6816.36) is close to 5-year high of 6852.73
The historical rank and industry rank for KYTHERA Biopharmaceuticals's PS Ratio or its related term are showing as below:
FRA:KYT'
s PS Ratio Range Over the Past 10 Years
Min: 9.55 Med: 28.71 Max: 6852.73
Current: 6816.36
During the past 5 years, KYTHERA Biopharmaceuticals's highest PS Ratio was 6852.73. The lowest was 9.55. And the median was 28.71.
FRA:KYT's PS Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.225
vs FRA:KYT: 6816.36
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of KYTHERA Biopharmaceuticals's PS Ratio
For the Drug Manufacturers - General subindustry, KYTHERA Biopharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KYTHERA Biopharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, KYTHERA Biopharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where KYTHERA Biopharmaceuticals's PS Ratio falls into.
KYTHERA Biopharmaceuticals PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
KYTHERA Biopharmaceuticals's Share Price of today is €66.74. KYTHERA Biopharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
KYTHERA Biopharmaceuticals (FRA:KYT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
KYTHERA Biopharmaceuticals PS Ratio Related Terms
Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
KYTHERA Biopharmaceuticals (FRA:KYT) Business Description
KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:KYT has been successfully added to your 